Solymbic

RSS
Withdrawn

This medicine's authorisation has been withdrawn

adalimumab
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

The marketing authorisation for Solymbic has been withdrawn at the request of the marketing-authorisation holder.

Solymbic : EPAR - Summary for the public

English (EN) (580.37 KB - PDF)

First published: Last updated:
View

български (BG) (665.09 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

español (ES) (559.95 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

čeština (CS) (640.44 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

dansk (DA) (554 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

Deutsch (DE) (563.02 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

eesti keel (ET) (552.38 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

ελληνικά (EL) (671.55 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

français (FR) (561.6 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

hrvatski (HR) (580.59 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

italiano (IT) (556.94 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

latviešu valoda (LV) (275.58 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

lietuvių kalba (LT) (584.96 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

magyar (HU) (633.6 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

Malti (MT) (628.45 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

Nederlands (NL) (558.9 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

polski (PL) (639.92 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

português (PT) (559.5 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

română (RO) (588.68 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

slovenčina (SK) (624.71 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

slovenščina (SL) (615.65 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

Suomi (FI) (553.67 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

svenska (SV) (554.21 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

Product information

Solymbic : EPAR - Product Information

English (EN) (2.42 MB - PDF)

First published: Last updated:
View

български (BG) (6.02 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

español (ES) (3.85 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

čeština (CS) (4.92 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

dansk (DA) (3.35 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

Deutsch (DE) (3.56 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

eesti keel (ET) (3.27 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

ελληνικά (EL) (6.23 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

français (FR) (3.98 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

hrvatski (HR) (3.68 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

íslenska (IS) (3.59 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

italiano (IT) (3.92 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

latviešu valoda (LV) (5.05 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

lietuvių kalba (LT) (3.84 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

magyar (HU) (5.02 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

Malti (MT) (5.28 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

Nederlands (NL) (3.65 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

norsk (NO) (3.45 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

polski (PL) (5.13 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

português (PT) (3.53 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

română (RO) (3.89 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

slovenčina (SK) (4.89 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

slovenščina (SL) (4.87 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

Suomi (FI) (3.75 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View

svenska (SV) (3.54 MB - PDF)

First published: 07/04/2017Last updated: 10/07/2018
View
Latest procedure affecting product information: IG/0946
22/06/2018
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Solymbic : EPAR - All Authorised presentations

English (EN) (514.38 KB - PDF)

First published: Last updated:
View

български (BG) (536.38 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

español (ES) (508.28 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

čeština (CS) (532.17 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

dansk (DA) (511.23 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

Deutsch (DE) (508.32 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

eesti keel (ET) (505.94 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

ελληνικά (EL) (549.49 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

français (FR) (509.49 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

hrvatski (HR) (511.79 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

íslenska (IS) (509.58 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

italiano (IT) (513.63 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

latviešu valoda (LV) (193.56 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

lietuvių kalba (LT) (509.22 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

magyar (HU) (522.74 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

Malti (MT) (534.14 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

Nederlands (NL) (507.42 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

norsk (NO) (507.91 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

polski (PL) (527.71 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

português (PT) (508.73 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

română (RO) (512.04 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

slovenčina (SK) (525.69 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

slovenščina (SL) (520.52 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

Suomi (FI) (514.13 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

svenska (SV) (508.72 KB - PDF)

First published: 07/04/2017Last updated: 07/04/2017
View

Product details

Name of medicine
Solymbic
Active substance
adalimumab
International non-proprietary name (INN) or common name
adalimumab
Therapeutic area (MeSH)
  • Arthritis, Psoriatic
  • Spondylitis, Ankylosing
  • Crohn Disease
  • Colitis, Ulcerative
  • Hidradenitis Suppurativa
  • Psoriasis
  • Arthritis, Rheumatoid
Anatomical therapeutic chemical (ATC) code
L04AB04

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Please refer to section 4.1 of the Summary of product characteristics in the product information document.

Authorisation details

EMA product number
EMEA/H/C/004373

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the ‘reference medicine’. For more information, see Biosimilar medicines.

Marketing authorisation holder
Amgen Europe B.V.

Minervum 7061
4817 ZK Breda
Netherlands

Opinion adopted
15/12/2016
Marketing authorisation issued
22/03/2017
Revision
2

Assessment history

Solymbic : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.46 MB - PDF)

First published: Last updated:
View

Solymbic : EPAR - Public assessment report

Reference Number: EMA/106921/2017

English (EN) (6.66 MB - PDF)

First published: Last updated:
View

CHMP summary of positive opinion for Solymbic

AdoptedReference Number: EMA/CHMP/41575/2017

English (EN) (559.71 KB - PDF)

First published: Last updated:
View

Related content

More information on Solymbic

Public statement on Solymbic: Withdrawal of the marketing authorisation in the European Union

Reference Number: EMA/7897/2019

English (EN) (59.31 KB - PDF)

First published:
View
This page was last updated on

Share this page

Back to top